Finance

Lists
Q2 2027 earnings • released • EPS beat +2.78% • Revenue beat +1.74%
See results
LUPIN:NSE
Lupin Ltd
₹1,988.10
+0.01%
(+0.100) 1D
Nov 6, 3:30:00 PM GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for LUPIN...
Open
₹1,985.50
High
₹1,996.90
Low
₹1,968.20
Mkt. cap
908.50B
Avg. vol.
726.15K
Volume
431.22K
Dividend
0.91%
Quarterly dividend
₹4.50
Ex-dividend date
Jul 17, 2026
P/E ratio
16.46
52-wk high
₹2,529.50
52-wk low
₹1,892.90
EPS
₹120.80
Shares outstanding
452.41M
No. of employees
26K
Open
₹1,985.50
High
₹1,996.90
Low
₹1,968.20
Mkt. cap
908.50B
Avg. vol.
726.15K
Volume
431.22K
Dividend
0.91%
Quarterly dividend
₹4.50
Ex-dividend date
Jul 17, 2026
P/E ratio
16.46
52-wk high
₹2,529.50
52-wk low
₹1,892.90
EPS
₹120.80
Shares outstanding
452.41M
No. of employees
26K
News stories
From web sources and news partners
Profile
Lupin Limited is an Indian multinational pharmaceutical company based in Mumbai. It is primarily a manufacturer of generic drugs, covering therapeutic areas such as paediatrics, cardiovascular, anti-infectives, diabetology, asthma and anti-tuberculosis.The company operates in multiple international markets including the United States, Japan, Europe, and Australia.. Wikipedia
About Lupin Ltd
CEOVinita D. Gupta
Employees26K
Founded1968
HeadquartersMumbai, Maharashtra, India
SectorHealth Care
IndustryPharmaceutical industry
Websitelupin.com
Last report
Nov 4, 2026
Fiscal period
Q2 2027
₹25.14 / ₹24.46
+2.78%beat
Revenue / Est. (INR)
78.27B / 76.94B
+1.74%beat
Fiscal Q2 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Revenue
Net income
All values in INR
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
71.68B
74.75B
82.77B
78.27B
Cost of goods sold
18.78B
24.90B
20.89B
20.08B
Cost of revenue
18.78B
24.90B
20.89B
20.08B
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
11.43B
13.85B
13.83B
14.24B
Operating expense
33.93B
31.74B
40.89B
43.23B
Total operating expenses
52.71B
56.64B
61.78B
63.31B
Operating income
18.97B
18.10B
20.99B
14.96B
Other non operating income
1.15B
-2.87B
1.30B
1.27B
EBT including unusual items
15.22B
19.28B
20.17B
15.80B
EBT excluding unusual items
19.49B
19.91B
21.05B
16.04B
Income tax expense
3.42B
4.59B
6.00B
4.24B
Effective tax rate
22.44%
23.82%
29.76%
26.86%
Other operating expenses
19.37B
14.55B
23.41B
24.38B
Net income
11.76B
14.60B
14.15B
11.55B
Net profit margin
16.40%
19.54%
17.10%
14.76%
Earnings per share
32.18
34.75
30.89
25.14
Interest and investment income
-
2.17B
-
-
Interest expense
-1.15B
-633.10M
-1.10B
-1.06B
Net interest expenses
-1.15B
1.54B
-1.10B
-1.06B
Depreciation and amortization charges
3.13B
3.34B
3.65B
4.61B
EBITDA
21.20B
20.81B
23.69B
19.66B
Gain or loss from assets sale
-
-
-
-
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps